August 20, 2014 7:27 AM ET


Company Overview of NEONC Technologies, Inc.

Company Overview

NEONC Technologies, Inc., a cancer biotherapy company, develops intranasal inhalation dosing therapies for the treatment of brain and lung cancers. The company was incorporated in 2008 and is based in Los Angeles, California.

10524 South La Cienega Boulevard

Los Angeles, CA 90304

United States

Founded in 2008



Key Executives for NEONC Technologies, Inc.

Chief Executive Officer
Chief Financial Officer
Senior Vice President of Corporate Affairs
Director of Engineering & Scientific Team and Director
Compensation as of Fiscal Year 2014.

NEONC Technologies, Inc. Key Developments

NEONC Technologies, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 03:30 PM

NEONC Technologies, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 03:30 PM. Venue: New York Academy of Sciences, New York, United States.

NEONC Technologies, Inc. Announces Clinical Testing of NEO100 in Treatment of Gliomas and Other Cancers

NEONC Technologies, Inc. announced that the company's NEO100 compound will undergo extensive clinical testing for treatment of gliomas and other cancers of the central nervous system. The clinical testing program was developed at meetings in Los Angeles on January 25-26 of the company's Scientific and Clinical Advisory Board, consisting of internationally prominent researchers and clinicians in the field of neuro-oncology. Unparalleled Success in Treating Deadly Brain Cancer: Malignant gliomas currently have no cure and are nearly always fatal to patients within 12-15 months of diagnosis. Research in Brazil published in April 2010 by Dr. Clovis da Fonseca and his team, who are also founders of NEONC, in glioma patients using intranasal delivery of POH, demonstrated unparalleled success treating this disease. The study included 89 adult patients with recurrent malignant glioblastoma multiforme (GBM) and 52 matched GBM patients in a historical untreated control group. Patients with recurrent primary GBM survived significantly longer than the untreated group. Patients with primary GBM treated with inhaled POH showed a survival advantage (5.9 months) compared with the control group (2.3 months). In addition, the side effects of treatment were almost nonexistent, even in patients treated for more than four years.

Similar Private Companies By Industry

Company Name Region
JRX Biotechnology, Inc. United States
Protherics Inc. United States
ConverGene LLC United States
Solidagex, Inc. United States
C5-6 Technologies Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEONC Technologies, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at